| First Author | Smyth MJ | Year | 2008 |
| Journal | Cancer Res | Volume | 68 |
| Issue | 8 | Pages | 3019-25 |
| PubMed ID | 18413772 | Mgi Jnum | J:133957 |
| Mgi Id | MGI:3784714 | Doi | 10.1158/0008-5472.CAN-07-6019 |
| Citation | Smyth MJ, et al. (2008) Interleukin 21 enhances antibody-mediated tumor rejection. Cancer Res 68(8):3019-25 |
| abstractText | Interleukin-21 (IL-21) is a cytokine with structural and sequence homology to IL-2 and IL-15 that has antitumor activity alone in mouse experimental tumor models and a tolerable safety profile in phase I trials in patients with metastatic melanoma and renal cell carcinoma. Several monoclonal antibodies (mAb) targeted at tumor-associated antigens also have improved antitumor activities in mice when used in combination with IL-21. Recently, we described a rational three antibody-based approach (triple mAb, TrimAb) to eradicating established mouse tumors that required the generation of tumor-reactive CD8(+) T cells and IFN-gamma. Herein, we show that sequentially combining TrimAb with recombinant IL-21 can significantly improve the antitumor activity of this combination against very advanced disease. These data further support the use of IL-21 in adjuvant settings where strong T cell-mediated immune responses to tumors can be generated. |
